首页 | 本学科首页   官方微博 | 高级检索  
     


Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case
Authors:Yatsuka Hibi  Tamae Ohye  Kimio Ogawa  Yoshimi Shimizu  Masahiro Shibata  Chikara Kagawa  Yutaka Mizuno  Shinya Uchino  Shinji Kosugi  Hiroki Kurahashi  Katsumi Iwase
Affiliation:1. Department of Endocrine Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
2. Division of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, 470-1192, Japan
3. Department of Surgery, Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Oita, 874-0932, Japan
5. MEN Consortium of Japan, Kyoto, Japan
4. Department of Medical Ethics and Medical Genetics, Kyoto University Graduate School of Public Health, Kyoto, 606-8501, Japan
Abstract:
We report a rare case with pheochromocytoma as the first manifestation of multiple endocrine neoplasia type 2A with RET mutation S891A. Bilateral pheochromocytomas were identified in a 54-year-old woman. Screening for RET revealed a rare S891A mutation located in the intracellular tyrosine kinase domain. This mutation was previously recognized as one of the mutations only in cases manifesting solely medullary thyroid carcinomas (MTCs). Since calcitonin stimulation test indicated positive result, total thyroidectomy was performed 1 year after the bilateral adrenalectomy, and C-cell hyperplasia was diagnosed by histopathological examination. Our report suggests that cases with S891A mutation, akin to those with other RET mutations, require screening for pheochromocytoma. In addition, it is indicated that calcitonin stimulation test should be performed even in the unaffected elder cases with S891A mutation although the mutation is classified as lowest risk group on MTC in guidelines.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号